ATE198710T1 - Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa - Google Patents

Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa

Info

Publication number
ATE198710T1
ATE198710T1 AT94914087T AT94914087T ATE198710T1 AT E198710 T1 ATE198710 T1 AT E198710T1 AT 94914087 T AT94914087 T AT 94914087T AT 94914087 T AT94914087 T AT 94914087T AT E198710 T1 ATE198710 T1 AT E198710T1
Authority
AT
Austria
Prior art keywords
polypeptide
novel polypeptide
activity against
inhibiting activity
against factor
Prior art date
Application number
AT94914087T
Other languages
English (en)
Inventor
Elisha P Zeelon
Moshe M Werber
Avigdor Levanon
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Application granted granted Critical
Publication of ATE198710T1 publication Critical patent/ATE198710T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94914087T 1993-04-09 1994-04-08 Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa ATE198710T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4580593A 1993-04-09 1993-04-09
PCT/US1994/003871 WO1994023735A1 (en) 1993-04-09 1994-04-08 Novel polypeptide having factor xa inhibitory activity

Publications (1)

Publication Number Publication Date
ATE198710T1 true ATE198710T1 (de) 2001-02-15

Family

ID=21939985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94914087T ATE198710T1 (de) 1993-04-09 1994-04-08 Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa

Country Status (14)

Country Link
EP (1) EP0696198B1 (de)
JP (1) JPH08511157A (de)
KR (1) KR960701649A (de)
AT (1) ATE198710T1 (de)
AU (1) AU682361B2 (de)
CA (1) CA2159218A1 (de)
DE (1) DE69426598T2 (de)
DK (1) DK0696198T3 (de)
ES (1) ES2155472T3 (de)
GR (1) GR3035722T3 (de)
IL (1) IL109259A0 (de)
NZ (1) NZ265507A (de)
PT (1) PT696198E (de)
WO (1) WO1994023735A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338665C (en) 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US8188224B2 (en) 2005-04-11 2012-05-29 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2008051178A2 (en) 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
US7811800B2 (en) 2005-04-11 2010-10-12 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
EP4635567A3 (de) 2009-06-25 2025-12-03 Horizon Therapeutics USA, Inc. Verfahren und kits zur prävention des infusionsreaktionsrisikos und antikörpervermittelter reaktionsverlust durch überwachung von serumharnsäure während der pegylierten harnasetherapie
US8685462B1 (en) 2012-09-17 2014-04-01 Biopep Solutions, Inc. Whole, leech saliva product and applications thereof
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN110234340A (zh) 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
EP0347376B1 (de) * 1988-06-11 1994-03-23 Ciba-Geigy Ag Polypeptide mit einer die Koagulierung hemmenden Wirkung
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86856A0 (en) * 1988-06-24 1988-11-30 Yissum Res Dev Co Bovine xa factor and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
PT696198E (pt) 2001-07-31
GR3035722T3 (en) 2001-07-31
IL109259A0 (en) 1994-07-31
DE69426598D1 (de) 2001-02-22
EP0696198B1 (de) 2001-01-17
DK0696198T3 (da) 2001-08-06
EP0696198A4 (de) 1999-01-27
AU6629194A (en) 1994-11-08
ES2155472T3 (es) 2001-05-16
DE69426598T2 (de) 2001-08-09
WO1994023735A1 (en) 1994-10-27
NZ265507A (en) 1998-09-24
AU682361B2 (en) 1997-10-02
JPH08511157A (ja) 1996-11-26
EP0696198A1 (de) 1996-02-14
CA2159218A1 (en) 1994-10-27
KR960701649A (ko) 1996-03-28
HK1013315A1 (en) 1999-08-20

Similar Documents

Publication Publication Date Title
ATE198710T1 (de) Neuartiges polypeptid mit einer inhibierenden aktivität gegen faktor xa
PL309398A1 (en) Interferon containing therapeutic composition
DE69128779D1 (de) Epitheline: neue cystein-reiche, den wachstum modulierende proteine
ATE275948T1 (de) Verwendung von adamantan derivaten zur herstellung eines medikaments zur glaukombehandlung
GB9614967D0 (en) Surface treatment process
ATE131493T1 (de) Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase
IL84852A0 (en) Molecular cloning and expression of human il-3
PL307258A1 (en) Peptides capable to block calcium canals with agelenopsis aperta
ATE162851T1 (de) Bakteriocin von lactococcus lactis subspezies lactis
EP0460072A4 (en) Human elastase inhibitor
DE69205154D1 (de) Verwendung von mindestens einem gereinigten peptid, welches durch kaseinhydrolyse hergestellt werden kann und opiataktivität hat, als aktiven bestandteil in der herstellung einer kosmetischen zusammensetzung.
MY128309A (en) Improvements relating to termite control
DE69004794D1 (de) Verwendung eines Polypeptids mit Interleukin 2-Aktivität zur Herstellung einer zur Behandlung von einfachen Pleurageschwüren bestimmten pharmazeutischen Zusammensetzung.
GB2287720B (en) Porous metal composite body
CA2004202A1 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
Rawczynska-Englert et al. Staphylococcal endocarditis after valve replacement(9 years of experience).
Lekan CORONA TREATMENT AS AN ADHESION PROMOTER FOR UV-/EB-CURABLE COATINGS
EP0181524A3 (de) Lymphokin
Vandenbergh Bacteria for expressing a polysaccharide depolymerase containing a novel recombinant plasmid.
Ligabue The liming intervention: Technical problems and solutions adopted.]
CA2505487A1 (en) Levobupivacaine and its use as an anaesthetic in obstetrics
CA2173207A1 (en) Levobupivacaine and its use as an anaesthetic in patients having or disposed to depressed myocardial contractility
CA2090121A1 (en) Uses of colony stimulating factor-1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee